127 related articles for article (PubMed ID: 9168303)
41. Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis.
Wrone-Smith T; Izban KF; Ergin M; Cosar EF; Hsi ED; Alkan S
Exp Hematol; 2001 May; 29(5):572-81. PubMed ID: 11376869
[TBL] [Abstract][Full Text] [Related]
42. Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils.
Luttmann W; Opfer A; Dauer E; Foerster M; Matthys H; Eibel H; Schulze-Osthoff K; Kroegel C; Virchow JC
Eur J Immunol; 1998 Jul; 28(7):2057-65. PubMed ID: 9692873
[TBL] [Abstract][Full Text] [Related]
43. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
44. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression.
de Totero D; Montera M; Rosso O; Clavio M; Balleari E; Foa R; Gobbi M
Hematol J; 2004; 5(2):152-60. PubMed ID: 15048066
[TBL] [Abstract][Full Text] [Related]
45. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines.
Dirks W; Schöne S; Uphoff C; Quentmeier H; Pradella S; Drexler HG
Br J Haematol; 1997 Mar; 96(3):584-93. PubMed ID: 9054667
[TBL] [Abstract][Full Text] [Related]
46. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
Komada Y; Sakurai M
Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
[TBL] [Abstract][Full Text] [Related]
47. Fas gene mutation in the progression of adult T cell leukemia.
Maeda T; Yamada Y; Moriuchi R; Sugahara K; Tsuruda K; Joh T; Atogami S; Tsukasaki K; Tomonaga M; Kamihira S
J Exp Med; 1999 Apr; 189(7):1063-71. PubMed ID: 10190897
[TBL] [Abstract][Full Text] [Related]
48. Innate immunity protein Tag7 (PGRP-S) activates lymphocytes capable of Fasl-Fas-dependent contact killing of virus-infected cells.
Sharapova TN; Ivanova OK; Prasolov VS; Romanova EA; Sashchenko LP; Yashin DV
IUBMB Life; 2017 Dec; 69(12):971-977. PubMed ID: 29083508
[TBL] [Abstract][Full Text] [Related]
49. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system.
McGahon AJ; Costa Pereira AP; Daly L; Cotter TG
Br J Haematol; 1998 Jun; 101(3):539-47. PubMed ID: 9633899
[TBL] [Abstract][Full Text] [Related]
51. Ceramide induces apoptosis in neuroblastoma cell cultures resistant to CD95 (Fas/APO-1)-mediated apoptosis.
Schaefer JT; Barthlen W; Schweizer P
J Pediatr Surg; 2000 Mar; 35(3):473-9. PubMed ID: 10726692
[TBL] [Abstract][Full Text] [Related]
52. Death receptor Fas/Apo-1/CD95 expressed by human placental cytotrophoblasts does not mediate apoptosis.
Payne SG; Smith SC; Davidge ST; Baker PN; Guilbert LJ
Biol Reprod; 1999 May; 60(5):1144-50. PubMed ID: 10208976
[TBL] [Abstract][Full Text] [Related]
53. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.
Gajate C; An F; Mollinedo F
Clin Cancer Res; 2003 Apr; 9(4):1535-45. PubMed ID: 12684430
[TBL] [Abstract][Full Text] [Related]
54. Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM.
Giordano C; De Maria R; Stassi G; Todaro M; Richiusa P; Giordano M; Testi R; Galluzzo A
Diabetologia; 1995 Dec; 38(12):1449-54. PubMed ID: 8786019
[TBL] [Abstract][Full Text] [Related]
55. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.
Wang D; Freeman GJ; Levine H; Ritz J; Robertson MJ
Br J Haematol; 1997 May; 97(2):409-17. PubMed ID: 9163608
[TBL] [Abstract][Full Text] [Related]
56. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid.
Müschen M; Warskulat U; Schmidt B; Schulz WA; Häussinger D
Biol Chem; 1998; 379(8-9):1083-91. PubMed ID: 9792441
[TBL] [Abstract][Full Text] [Related]
57. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
58. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
59. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
60. Fas resistance of leukemic eosinophils is due to activation of NF-kappa B by Fas ligation.
Qin Y; Camoretti-Mercado B; Blokh L; Long CG; Ko FD; Hamann KJ
J Immunol; 2002 Oct; 169(7):3536-44. PubMed ID: 12244143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
